Leerink Partnrs Has Positive View of DexCom FY2028 Earnings
Leerink Partners has raised its FY2028 earnings per share (EPS) estimate for DexCom, Inc. to $3.83, up from $3.82. The consensus estimate for the current full-year earnings is $2.03 per share. DexCom reported $0.48 EPS for the last quarter, exceeding expectations. Analysts have given DexCom a consensus rating of "Moderate Buy" with a target price of $99.89. The stock opened at $80.77, with a market cap of $31.67 billion and a P/E ratio of 56.09. Institutional investors hold 97.75% of the stock.
- DexCom Stock: Earnings Beat and New Market Access Drive Bull Case
DexCom, Inc. (NASDAQ:DXCM - Free Report) - Stock analysts at Leerink Partnrs raised their FY2028 earnings per share (EPS) estimates for DexCom in a report released on Wednesday, July 30th. Leerink Partnrs analyst M. Kratky now expects that the medical device company will earn $3.83 per share for the year, up from their previous estimate of $3.82. The consensus estimate for DexCom's current full-year earnings is $2.03 per share. Leerink Partnrs also issued estimates for DexCom's FY2029 earnings at $4.41 EPS.
DexCom (NASDAQ:DXCM - Get Free Report) last announced its quarterly earnings results on Wednesday, July 30th. The medical device company reported $0.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.45 by $0.03. DexCom had a return on equity of 32.05% and a net margin of 13.29%. The company had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. During the same period in the prior year, the company earned $0.43 earnings per share. The company's revenue for the quarter was up 15.2% compared to the same quarter last year.
- 3 New ETFs Finding Early Traction With Investors
DXCM has been the subject of several other reports. Barclays increased their price target on DexCom from $93.00 to $98.00 and gave the stock an "equal weight" rating in a report on Wednesday. Wall Street Zen upgraded DexCom from a "hold" rating to a "buy" rating in a report on Friday, July 18th. Piper Sandler increased their price target on DexCom from $90.00 to $100.00 and gave the stock an "overweight" rating in a report on Thursday. Truist Financial started coverage on DexCom in a report on Monday, June 16th. They issued a "buy" rating and a $102.00 price target for the company. Finally, Mizuho increased their price target on DexCom from $95.00 to $100.00 and gave the stock an "outperform" rating in a report on Wednesday, July 16th. Four investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $99.89.
Get Our Latest Analysis on DexCom
DexCom Stock Down 9.3%
- Top 3 Stocks to Watch: Options Traders Bet on Big Gains
Shares of DexCom stock opened at $80.77 on Friday. DexCom has a 1 year low of $57.52 and a 1 year high of $93.25. The business has a 50-day moving average of $84.67 and a two-hundred day moving average of $80.62. The company has a market capitalization of $31.67 billion, a P/E ratio of 56.09, a price-to-earnings-growth ratio of 1.90 and a beta of 1.44. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.50 and a quick ratio of 1.32.
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of DXCM. Horizon Investments LLC boosted its stake in shares of DexCom by 2.2% during the 1st quarter. Horizon Investments LLC now owns 5,608 shares of the medical device company's stock worth $383,000 after acquiring an additional 123 shares during the period. Nia Impact Advisors LLC boosted its stake in shares of DexCom by 1.4% during the 4th quarter. Nia Impact Advisors LLC now owns 9,850 shares of the medical device company's stock worth $766,000 after acquiring an additional 140 shares during the period. Covestor Ltd boosted its stake in shares of DexCom by 15.6% during the 4th quarter. Covestor Ltd now owns 1,109 shares of the medical device company's stock worth $86,000 after acquiring an additional 150 shares during the period. Wedbush Securities Inc. lifted its holdings in DexCom by 1.2% during the 1st quarter. Wedbush Securities Inc. now owns 13,168 shares of the medical device company's stock worth $899,000 after purchasing an additional 157 shares during the last quarter. Finally, Argonautica Private Wealth Management Inc. lifted its holdings in DexCom by 3.2% during the 1st quarter. Argonautica Private Wealth Management Inc. now owns 5,958 shares of the medical device company's stock worth $407,000 after purchasing an additional 182 shares during the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.
Insider Buying and Selling
In related news, Director Nicholas Augustinos sold 3,672 shares of the stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $82.80, for a total transaction of $304,041.60. Following the completion of the transaction, the director directly owned 33,411 shares of the company's stock, valued at approximately $2,766,430.80. This represents a 9.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Michael Jon Brown sold 10,000 shares of the stock in a transaction that occurred on Friday, May 23rd. The shares were sold at an average price of $84.28, for a total value of $842,800.00. Following the transaction, the executive vice president directly owned 95,602 shares of the company's stock, valued at $8,057,336.56. This trade represents a 9.47% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 28,656 shares of company stock valued at $2,412,191. 0.32% of the stock is currently owned by company insiders.
About DexCom
(Get Free Report)DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.
See Also
- Five stocks we like better than DexCom
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Newmont's Financial Strength Sets a High Bar for Gold Miners
- Investing in Travel Stocks Benefits
- Golden Cross Alert: 3 Stocks With Serious Upside Potential
- Growth Stocks: What They Are, Examples and How to Invest
- Big Beat, Bigger Plans: AEP Stock Powers Up on Data Center Boom
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in DexCom Right Now?
Before you consider DexCom, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DexCom wasn't on the list.
While DexCom currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
